Key result
Early enzyme replacement therapy regresses hypertrophy and improves cardiac function in infantile Pompe disease.
Why the study?
Cardiac involvement in Pompe disease varies by clinical phenotype and age of onset, requiring adapted cardiovascular assessment and cardiologist involvement in recognizing atypical cardiac phenotypes and long-term management.
This review summarizes the pathophysiology, multimodality imaging assessment, and therapeutic perspectives of cardiac involvement in Pompe disease, highlighting the prominent cardiomyopathy in classic infantile-onset disease that regresses with early enzyme replacement therapy.
Answers are grounded in this paper and cite their sources.
Reinforces early enzyme replacement for cardiac regression in infantile Pompe; extends multimodal imaging insights but leaves optimal protocols open.
Pompe disease, also known as glycogen storage disease type II or acid maltase deficiency, is a rare autosomal recessive lysosomal storage disorder caused by pathogenic variants in the GAA gene encoding lysosomal acid α-glucosidase. Deficient enzyme activity results in progressive intralysosomal glycogen accumulation, particularly in skeletal, respiratory, and, in the classic infantile phenotype, cardiac muscle. Cardiac involvement is most prominent in classic infantile-onset Pompe disease, in which severe myocardial hypertrophy, ventricular remodeling, diastolic dysfunction, and electrical abnormalities may develop early in life. In contrast, clinically significant cardiac disease is uncommon in late-onset Pompe disease, although subtle abnormalities have occasionally been identified using sensitive cardiovascular imaging techniques. Cardiovascular assessment therefore needs to be adapted to the clinical phenotype and age of onset. Electrocardiography and echocardiography remain the principal first-line investigations, whereas speckle-tracking echocardiography and cardiac magnetic resonance may provide complementary information in selected patients. Cardiac magnetic resonance allows accurate assessment of ventricular volumes and mass and provides tissue characterization, although current evidence remains limited and heterogeneous. Enzyme replacement therapy has substantially changed the natural history of classic infantile Pompe disease, with regression of myocardial hypertrophy and improvement in cardiac function when treatment is initiated early. The cardiovascular response in late-onset disease appears considerably less pronounced. This review summarizes the mechanisms of cardiac involvement in Pompe disease, its clinical and electrocardiographic manifestations, the contribution of multimodality cardiovascular imaging, practical diagnostic considerations for cardiologists, and current and emerging therapeutic perspectives. Particular emphasis is placed on the role of the cardiologist in recognizing atypical cardiac phenotypes and participating in multidisciplinary long-term management.
No takes yet. Share an insight, caveat, or question.
N. Annane² Z. Bennoui*¹ (2026) conducted a review in Pompe disease (glycogen storage disease type II). Enzyme replacement therapy and multimodality cardiovascular imaging was evaluated. Enzyme replacement therapy regresses myocardial hypertrophy and improves cardiac function in classic infantile Pompe disease when started early, whereas responses in late-onset disease are less pronounced.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: